Clinical Trial Update: Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097) [Phase 3]

View source ↗

Summary

Aprepitant (MK-0869) completed a Phase 3 trial evaluating its effectiveness in preventing chemotherapy-induced nausea and vomiting in adolescent participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• Aprepitant (aprepitant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Vomiting | Phase 3 | Status: COMPLETED